All articles by GlobalData Healthcare

  1. New positive data presented for Janssen’s ponesimod remains questionable

    Janssen, a subsidiary of Johnson & Johnson, presented positive top-line results from the Phase III OPTIMUM study at the annual…
    Read More…

    18 Sep
  2. Chasing Cancer considers how to improve patient access to cancer therapies

    A Washington Post live event entitled Chasing Cancer was held in Boston, Massachusetts, US, on 4 September, to consider strategies…
    Read More…

    16 Sep
  3. First-in-class HIF-2a inhibitor could revolutionise renal cell carcinoma treatment algorithm

    Following the acquisition of Peloton Therapeutics in July 2019, Merck is accelerating the development of the first-in-class oral, selective hypoxia-inducible…
    Read More…

    13 Sep
  4. Trial halted early as Nuplazid shows strong efficacy in dementia-related psychosis

    Acadia’s Nuplazid (pimavanserin) has performed so well in Phase III clinical trial that the trial has been halted early. Nuplazid…
    Read More…

    13 Sep
  5. Stivarga’s potential in combination therapy for metastatic colorectal cancer

    Bayer’s Stivarga (regorafenib) has been widely accepted as a monotherapy treatment option for patients with refractory metastatic colorectal cancer (CRC). …
    Read More…

    13 Sep
  6. Novartis still hoping for Entresto success in heart failure with preserved ejection fraction

    At this year’s European Society of Cardiology Congress (ESC) in Paris, Novartis announced the results of two trials, PROVE-HF and…
    Read More…

    13 Sep
  7. Exelixis and Aurigene collaborate to accelerate novel therapies for cancer

    On July 31, Exelixis announced its new collaboration with Aurigene Discovery Technologies Ltd (Aurigene), an India-based biotechnology company and a…
    Read More…

    11 Sep
  8. Esperion’s cholesterol-lowering drug has positive Phase II results for Type 2 diabetes patients

    Espiron’s Phase II trial of their cholesterol-lowering bempedoic acid + ezetimibe combination drug in patients with type 2 diabetes has…
    Read More…

    5 Sep
  9. JAK inhibitor ulcerative colitis trial delays triggered by the paucity of eligible patients

    Trials for JAK inhibitors in ulcerative colitis (UC) have faced, or still are challenged by, recruitment delays as already approved…
    Read More…

    5 Sep
  10. Non-Hodgkin’s lymphoma novel pipeline is diverse and dominated by combination therapies

    The late-stage pipeline for non-Hodgkin’s lymphoma (NHL) contains a diverse range of mechanisms of action.  Non-Hodgkin’s lymphoma treatment The figure…
    Read More…

    4 Sep
Close
Close
Close

Go Top